The newer BCR/ABL tyrosine kinase inhibitors dasatinib and nilotinib are more potent than imatinib and result in higher rates of early complete cytogenetic response and major molecular response. They also demonstrate significant activity against many resistant mutations but they are not effective against the BCR/ABL/T3151 mutation. Resistance may develop to these newer agents as well.
To read more about the treatment of CML, click here.
| Related Resources |
Medscape © 2014
WebMD, LLC
Cite this: Fast Five Quiz: How Prepared Are You to Address Chronic Myelogenous Leukemia? - Medscape - Nov 11, 2014.
Comments